Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
5.95
-1.01 (-14.46%)
At close: Mar 28, 2025, 4:00 PM
6.00
+0.05 (0.91%)
After-hours: Mar 28, 2025, 7:46 PM EDT
Candel Therapeutics Stock Forecast
Stock Price Forecast
The 4 analysts with 12-month price forecasts for Candel Therapeutics stock have an average target of 21, with a low estimate of 15 and a high estimate of 25. The average target predicts an increase of 253.24% from the current stock price of 5.95.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Candel Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 4 | 4 |
| Buy | 2 | 0 | 0 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 1 | 1 | 1 | 4 | 4 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +219.60% | Mar 14, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Maintains $20 → $25 | Strong Buy | Maintains | $20 → $25 | +320.52% | Feb 26, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $19 | Strong Buy | Reiterates | $19 | +219.60% | Feb 26, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +320.52% | Feb 20, 2025 |
| Canaccord Genuity | Canaccord Genuity | Strong Buy Initiates $20 | Strong Buy | Initiates | $20 | +236.42% | Feb 19, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.14
from -1.74
EPS Next Year
-1.64
from -1.14
Revenue Forecast
| Revenue | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | n/a | n/a | 384.0M | |
| Avg | n/a | n/a | 373.0M | |
| Low | n/a | n/a | 358.4M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2028 | 2029 |
|---|---|---|---|---|
| High | - | - | - | |
| Avg | - | - | - | |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.97 | -1.00 | -0.80 |
| Avg | -1.14 | -1.64 | -1.04 |
| Low | -1.28 | -2.23 | -1.25 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.